First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
BUSINESS ACCOUNT
Sign up for a business account to:
-
Access reports individually or via Subscription
-
Receive monthly invoices with payment via CSA or hard dollars
Get access to other exclusive features
-
Analyst access
-
Free Trial Subscriptions
-
Team account with shared subscriptions
-
Advanced analytics to track research consumption and performance
Christophe DOMBU
- Christophe DOMBU
Biocorp could achieve decisive milestones in 2017
For the past 2 years, Biocorp has initiated major business transformations in order to become a key player in the booming market of connected health. The company has developed a range of connected devices addressing major healthcare issues. The company made significant advances in 2016 by signing 4 partnerships agreements with pharmaceutical players. Based on these agreements, Biocorp and its partners initiated preliminary studies assessing the feasibility and the performance of Biocorp’s con...
Christophe DOMBU
- Christophe DOMBU
Implanet’s Jazz sales up 18% in 2016
​ Implanet published its 2016 sales, confirming the good dynamics of its marketing activity (+18% compared to 2015, from €6.7 M to €7.8 M). The company benefits from the growing adoption of its lead product, the Jazz Band, especially in France and the US. Given the company’s efforts to further accelerate the adoption of Jazz, we believe that the company has the means to maintain this trend in 2017. Although the reported sales are slightly below our forecast, we remain confident on the co...
Christophe DOMBU
- Christophe DOMBU
Implanet confirms clinical benefits of Jazz implants after three years...
​Implanet released additional clinical data showing the good performance of the Jazz band implant in correcting large spine deformitiesinadolescents.Datawerepublishedinawhitepaper by French KOLs, giving Implanet additional arguments to convince more surgeons to adopt the company’s product, while expandingitsscopeofapplication.Implanet recently secured a € 6.9Mfollow-onfinancing.Theoperationreceivedastrongsupportfromseinstitutionalinvestorsdespitedifficultmarketconditions.The funds will sup...
Christophe DOMBU
- Christophe DOMBU
Biocorp announced a 23% increase of revenues for H1-2016 and a new par...
Biocorp is a medical device supplier for large pharmaceutical companies, and reported encouraging interim results. The company recorded a 23% increase of its revenue to €1.6 M, mainly attributedto sales on its historical activity. On the other hand, the company reported a 32% increase in operational expenses (€3.7 M), mainly due to investments made to support and anticipate the growthof the company’s business. Net loss for the first half of 2016 was €1.9 M, compared to €0.8 M as of Jun...
Christophe DOMBU
- Christophe DOMBU
Extended US patent protection for Quantum Genomics’ drug candidates
Quantum Genomics announced that the United States Patent and Trademark Office (USPTO) granted the Company two patents protecting its technology until 2031 and 2033. Quantum Genomics is specializing in cardiovascular diseases with first-in class drug candidates, Brain Aminopeptidase A inhibitors. The Company has also made important progress on its developmentplan. For instance, a Phase IIa trial in heart failure has just been authorized in France. The Company also completed QGC001 Phase IIa trial...
Christophe DOMBU
- Christophe DOMBU
First positive DSMB with QGC001 in hypertension
Quantum Genomics, a French biopharmaceutical company developing cutting-edge drugs in the field of cardiovascular diseases, received the first positive recommendation from the Data Safety Monitoring Board (DSMB) to continue QGC001’s phase 2a trial in hypertension. QGC001 is a first-in-class drug candidate addressing resistant hypertension, a serious condition affecting 100 to 150 million people worldwide, for which there is currently no effective drug. According to the World Health Organizatio...